| Literature DB >> 36232918 |
Saeed Alshahrani1, Hani M Ali Thubab1, Abdulrahman M Ali Zaeri1, Tarique Anwer1, Rayan A Ahmed1, Abdulmajeed M Jali1, Marwa Qadri1, Yousra Nomier1, Sivakumar S Moni2, Mohammad F Alam1.
Abstract
Cyclophosphamide is an anticancer drug with a wide spectrum of clinical uses, but its typical side effects are multiple complications, including nephron toxicity. The possible molecular mechanism of the nephroprotective action of sesamin (SM) against cyclophosphamide (CP) induced renal toxicity was investigated in rats by understanding oxidative stress and inflammatory cytokines. In this study, rats were arbitrarily grouped into the following four groups: a normal control group (CNT); a CP-induced toxicity group; a treatment group with two doses of sesamin SM10 and SM20; a group with sesamin (SM20) alone. A single dose of CP (150 mg/kg body, i.p.) was administered on day 4 of the experiments, while treatment with SM was given orally for seven days from day 1. The group treated with SM showed a significant protective effect against CP-induced renal damage in rats. Treatment with SM significantly increased the antioxidant enzymes (GSH, CAT, and SOD) and reduced malondialdehyde (MDA) levels. Thus, SM significantly overcame the elevated kidney function markers (creatinine, blood urea nitrogen, and uric acid) by attenuating oxidative stress. The SM also significantly reduced the elevated cytokines (IL-1β and TNFα) and caspase-3 in the treated group. Histopathological studies confirmed the protective effect of sesamin (SM) on CP-induced nephrotoxicity. In conclusion, the current findings support the nephroprotective effect of sesamin against CP-induced renal injury.Entities:
Keywords: apoptosis; cyclophosphamide; inflammatory cytokines; nephroprotective; oxidative stress; sesamin
Mesh:
Substances:
Year: 2022 PMID: 36232918 PMCID: PMC9569534 DOI: 10.3390/ijms231911615
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Effect of SM on serum markers against CP-induced nephrotoxicity.
| Test Group | Blood Urea Nitrogen (mg/dL) | Uric Acid (mg/dL) | Creatinine (mg/dL) |
|---|---|---|---|
| CNT | 18.66 ± 2.58 | 4.57 ± 1.18 | 0.81 ± 0.08 |
| CP | 50.16 ± 3.97 a | 16.71 ± 2.64 b | 2.06 ± 0.44 c |
| SM10 + CP | 29.16 ± 4.71 d | 9.36 ± 1.66 e | 1.57 ± 0.78 f |
| SM20 + CP | 21.16 ± 2.79 g | 5.63 ± 1.32 h | 0.91 ± 0.1 i |
| SM20 | 19.00 ± 3.03 j | 4.84 ± 1.47 k | 0.85 ± 0.04 l |
Data presented as mean ± standard deviation where n = 6, a p < 0.0001 vs. CNT, b p < 0.0001 vs. CP, c p < 0.0001 vs. CNT; d p < 0.0001 vs. CP, e p > 0.05 vs. CP, f p < 0.0001 vs. CP; g p < 0.0001 vs. CP, h p < 0.001 vs. CP, i p < 0.0001 vs. CP; j,k,l p > 0.05 vs. CNT.
Effects of SM on oxidative stress against CP-induced renal toxicity.
| Test Group | MDA | GSH | CAT | SOD |
|---|---|---|---|---|
| CNT | 9.07 ± 1.37 | 21.95 ± 3.39 | 15.01 ± 2.41 | 33.89 ± 1.07 |
| CP | 27.3 ± 3.65 ** | 6.23 ± 1.25 ## | 5.45 ± 1.30 a | 13.35 ± 3.45 $$ |
| SM10 + CP | 15.66 ± 2.98 *** | 12.89 ± 2.17 ### | 10.74 ± 1.76 b | 25.42 ± 4.35 $$$ |
| SM20 + CP | 10.50 ± 1.49 *** | 19.89 ± 2.43 ### | 12.98 ± 1.74 b | 33.22 ± 1.58 $$$ |
| SM20 | 10.12 ± 1.20 * | 21.027 ± 2.25 # | 14.15 ± 2.65 c | 34.04 ± 3.55 $ |
Data represent the protective effects of SM on oxidative stress markers (MDA, GSH, CAT and SOD) level against CP-induced nephrotoxicity. Data represented in mean ± SD (n = 6). * p > 0.05 vs. CNT, ** p < 0.0001 vs. CNT and *** p < 0.0001 vs. CP. # p > 0.05 vs. CNT, ## p < 0.0001 vs. CNT, ### p < 0.0001 vs. CP, c p > 0.05 vs. CNT, b p < 0.0001 vs. CP, a p < 0.0001 vs. CNT. $ p > 0.05 vs. CNT, $$ p < 0.0001 vs. CNT, $$$ p < 0.0001 vs. CP. Abbreviation; MDA: malondialdehyde, CNT: control, CP: cyclophosphamide, GSH: glutathione, CAT: catalase, SOD: superoxide dismutase, SM: sesamin.
Figure 1Protective effects of SM on renal inflammatory cytokine (IL-1β) level against CP-induced nephrotoxicity. Value denoted in mean ± SD (n = 6). **** p < 0.0001 vs. CNT, **** p < 0.0001 vs. CP and ns p > 0.05 vs. CNT, ns p > 0.05 SM10 vs. CP.
Figure 2Protective effects of SM on renal inflammatory cytokine (TNFα) level against CP-dependent nephrotoxicity. Value denoted in mean ± SD (n = 6). **** p < 0.0001 vs. CNT, *** p < 0.001 vs. CP, **** p < 0.0001 vs CP and ns p > 0.05 vs. CNT,. Abbreviation; CNT: control, CP: cyclophosphamide, SM: sesamin, TNFα: tumor necrosis factor alpha.
Figure 3Protective effects of SM on renal apoptotic marker (Caspase 3) level against CP-induced nephrotoxicity. Value denoted in mean ± SD (n = 6). **** p < 0.0001 vs. CNT, **** p < 0.0001 vs. CP and ns p > 0.05 vs. CNT. Abbreviation; CNT: control, CP: cyclophosphamide, SM: sesamin.
Figure 4Protective effects of sesamin against cyclophosphamide induced renal toxicity. Hematoxylin and eosin (H and E) staining indicates (A) normal control (CNT) without any abnormality; (B) CP intoxication with clear abnormality such as necrosis in GL, PT, and DT. (C) SM10 + CP and (D) SM20 + CP is sesamin treatment with improvement in renal architect. (E) SM20 no significant changes in renal architect. Scale bar is 50 px.